We are Nyxoah

Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Genio® implant

What is Obstructive Sleep Apnea

 

OSA and health risks

OSA is the most common sleep disordered breathing condition, affecting globally around 936 million people between 30 and 69 years of age, of whom 425 million suffer from moderate to severe OSA, requiring treatment[[Benjafield, Adam V et al. Estimation of the global prevalence and burden of obstructive sleep apnea: a literature-based analysis. Lancet Respir Med 2019 Published Online 9 July 2019 http://dx.doi.org/10.1016/S2213-2600(19)30198-5]].

Left untreated, OSA is associated with increased mortality risk[[Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078]] and comorbidities, including cardiovascular diseases, depression and stroke.

Clinical studies have shown that the mortality rate of non-treated patients suffering from OSA increases significantly over time[[Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.]] . Untreated OSA is associated with a two-times more risk of stroke[[Wake up America: a national sleep alert : report of the National Commission on Sleep Disorders Research (1994)]] and five-times more risk of cardiovascular mortality[[Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.]]. OSA increases the risk of heart failure by 140%[[Daniel Bratton. CPAP vs MA Devices and Blood Pressure in Patients With Obstructive Sleep ApneaA Systematic Review and Meta-analysis. Jama 2015]].

Title

Nyxoah in the news

Paragraphs
Date
24th June, 2020
Text

Nyxoah receives IDE approval from the U.S. Food and Drug Administration (FDA) for its DREAM study

 

Read more

Date
9th March, 2020
Text

Successful first implantation of two patients in Benelux with the Genio® system

 

Read more

Date
12th Feb, 2020
Text

Nyxoah raises €25 million in private funding round

 

Read more

bubble
bubble
bubble
bubble
bubble
Cookie Settings